• Oncomine was conceived by physicians, scientists, and software engineers at the University of Michigan.
• Oncomine 1.0 consists of 40 microarray data sets and nearly 100 pre-computed differential expression analyses. This version also includes analysis tools designed to allow users to query differential expression of a gene across all the collected data sets.
• Oncomine 2.0 increases the number of analyzed data sets to 65 and adds a co-expression module. In addition, an improved user interface is developed, and scalable vector graphics (SVG) are adopted for visualizing gene expression data and analyses.
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
Science 2005 Oct 28;310(5748):644-8.
• Mining for regulatory programs in the cancer transcriptome.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.
Nat Genet. 2005 Jun; 37(6):579-83.
• Integrative analysis of the cancer transcriptome.
Rhodes DR, Chinnaiyan AM.
Nat Genet. 2005 Jun;37 Suppl:S31-7. Review.
• Oncomine 3.0 includes significant additions in data and functionality. A semi-automated data pipeline was developed that allowed for a substantial increase in the number of collected data sets to 118, and the number of profiled cancer and normal tissue samples to nearly 10,000. In addition, more than 1,000 gene expression signatures were derived by grouping the samples based on curated sample facts ranging from cancer diagnosis, transforming mechanism, and patient survival. Additional analysis methods, including Molecular Concepts analysis, Meta-analysis, and Cancer Outlier Profile Analysis (COPA) were also developed.
• Compendia Bioscience is founded by Arul Chinnaiyan and Dan Rhodes in February 2006 with the goal of building a commercial version of Oncomine that would have a greater ability to impact drug development and clinical practice. Compendia licenses Oncomine and related technologies from the University of Michigan in February of 2006, and signs contracts with its first customers in March of 2006.
• Compendia partners with Ingenuity Systems.
• Oncomine Concepts Map combines nearly 7,000 Oncomine cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.
• Awarded $2.4 million SBIR Fast Track Award from the National Cancer Institute to support the project entitled "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development".
• Research Premium Edition launches. Enterprise Edition launches.
• Compendia given Product Innovator of the Year Award from the Michigan Business Review.
• A novel analysis method called Meta-COPA is introduced.
• Renewal rate for Oncomine is 100%.
• Compendia is awarded $1.75 million from Michigan's 21st Century Jobs Fund.
• Oncomine is a key tool used to discover SPINK1 as a key new therapeutic target and biomarker for prostate cancer.
• Compendia partners with Ricerca Biosciences to deliver a new product, OncoPredictor, which leverages genetic data to improve cancer drug development.
• Compendia reveals a completely redesigned Oncomine. While improved user experience was the driving force in Oncomine Concepts Edition 4.0, the entire Oncomine database was also scrutinized in an effort to standardize and catalog all data points.
• Oncomine 4.0 Research Edition released and freely available for academic and non-profit users.
• Oncomine Power Tools launch.
• The NCI awards $1.3 million in SBIR Fast Track funds to Compendia Bioscience to incorporate micro-RNA data and analyses into the Oncomine platform.
• Compendia partners with AltheaDx to develop OncoScore, a novel assay to measure the full biological variability of each cancer type.
Compendia Bioscience celebrates its fifth anniversary with 30 staff and 21,000+ Oncomine users.
COMPENDIA BIOSCIENCE AND H3 BIOMEDICINE ANNOUNCE STRATEGIC COLLABORATION TO APPLY CANCER GENOMICS TO DISCOVER AND DEVELOP NEXT GENERATION CANCER THERAPEUTICS
Compendia and H3 will work together to mine data from The Cancer Genome Atlas (TCGA) to discover novel therapeutic targets and biomarkers to support drug development.
ONCOMINE CONTRIBUTES TO INTEGRATIVE GENOMIC ANALYSIS OF LETHAL CASTRATION-RESISTANT PROSTATE CANCER
A study by researchers from the University of Michigan, Yale School of Public Health, Brown University and Compendia Bioscience was published in Nature. The study is notable for its comprehensive genomic profiling of patients with pre-treated lethal metastatic disease, providing insights into mechanisms of resistance.
LIFE TECHNOLOGIES ACQUIRES COMPENDIA BIOSCIENCE
The Compendia acquisition will enhance Life's companion diagnostics effort and positions the company as a partner of choice for pharma.